MARKET WIREYahoo Finance • 9h ago
Immix Biopharma (IMMX) Stock Sees Modest Fair Value Lift After Split Analyst RevisionsYahoo Finance report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
Why IMMX Stock dropped -3.76% Today — RQD Quant Desk Flash
$7.68 -3.76% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $7.61
Immix Biopharma Inc. (IMMX) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $661.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on IMMX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is IMMX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Immix Biopharma Inc. (NASDAQ: IMMX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $7.68 (-3.76% 1D, market cap $661.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMMX ranks #873 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does IMMX compare to ANL and LXRX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMMX carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ANL (Adlai Nortye Group Ltd.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $662.0M) and LXRX (Lexicon Pharmaceuticals Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -31.5%, cap $658.5M). Among the 5-stock peer group, IMMX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for IMMX?
▼
Per IMMX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001873835), Immix Biopharma Inc. generated $0 in revenue, -$29.4M in net income, and -$24.7M in free cash flow against $104.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $7.61 (-0.87%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-13% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMMX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY IMMX SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (34% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (21% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$9.25-11.1% Next Q
37
Q2 (-2Q)Grade E$8.22-1.9% Next Q
34
Q3 (-1Q)Grade E$8.06-4.7% Next Q
32
CurrentGrade E$7.68-9.8% Hist 90D α
29
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a IMMX Turnaround Squeeze
While IMMX currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.91) and Max Pain ($8.06) forces dealer call-delta covering toward $15.86.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMMX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMMX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IMMX Stock dropped -3.76% Today — RQD Quant Desk Flash
Immix Biopharma Inc. (IMMX) dropped -3.76% to $7.68, trading at 39% of its 52-week range ($2.85 – $15.1). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 39% of its 52-week range ($2.85 – $15.1) with RSI-14 at 35.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $7.68 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live IMMX Headlines & Catalysts
MARKET WIREInvesting.com • 12h ago
Morgan Stanley initiates Immix Biopharma stock with overweight ratingInvesting.com report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 15h ago
Immix Biopharma, Inc. Estimates – NASDAQ:IMMXTradingView report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall Street • 18h ago
Immix Biopharma (NasdaqCM:IMMX) Stock PriceSimply Wall Street report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGlobeNewswire • 21h ago
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
BlackRock reports a passive stake above 5% in Immix Biopharma (IMMX).Stock Titan report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
CATALYSTTradingView • 1d ago
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?TradingView report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMMX)
- ✓Walkthrough of IMMX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IMMX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.99%🛡️ HOLDING TREND SUPPORT
2026-11-02O $8.12H $8.12L $7.68C $7.68VOL 1.07M
RES: $17.99SUP: $7.59SMA50: $10.91SMA200: $9.50
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IMMX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on IMMX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IMMX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMMX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMMX)
Health Care Rank #873 of 1016
⚔️ ANL vs IMMX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IMMX vs. ANL, LXRX, ABUS, BCAX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Immix Biopharma Inc. (IMMX) ranks #873 by composite RQD confidence (29/100, grade E) and #407 by equity capitalization ($661.6M). Within this direct 5-issuer industry benchmark cohort, IMMX leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with IMMX at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMMX
ACTIVE
Immix Biopharma Inc. | E | 29/100 | — | — | -35.0% | -3.76% | $661.6M | Benchmark Subject |
| ANL Adlai Nortye Group Ltd. | D | 47/100 | — | — | — | -7.10% | $662.0M | /anl-vs-immx → |
| LXRX Lexicon Pharmaceuticals Inc. | E | 27/100 | — | 96.0% | -31.5% | -4.05% | $658.5M | /lxrx-vs-immx → |
| ABUS Arbutus Biopharma Corporation | E | 18/100 | — | — | -35.0% | -1.64% | $656.0M | /abus-vs-immx → |
| BCAX Bicara Therapeutics Inc. | E | 30/100 | — | — | -35.0% | -6.17% | $643.9M | /bcax-vs-immx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001873835In its most recent audited fiscal period (FY2025, filed 2025-12-31), Immix Biopharma Inc. (IMMX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$29.4M, operating cash flow of -$23.9M, and free cash flow of -$24.7M (-56.4% YoY). On the balance sheet, IMMX closed FY2025 with $104.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$29.4M | -$23.9M | -$24.7M | $104.8M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$21.6M | -$14.6M | -$15.8M | $22.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$15.4M | -$11.4M | -$11.4M | — | — |
3. IMMX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IMMX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Immix Biopharma Inc. (NASDAQ: IMMX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $7.68 (-3.76% 1D, market cap $661.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMMX ranks #873 in composite RQD confidence.
How does IMMX compare to ANL and LXRX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMMX carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ANL (Adlai Nortye Group Ltd.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $662.0M) and LXRX (Lexicon Pharmaceuticals Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -31.5%, cap $658.5M). Among the 5-stock peer group, IMMX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IMMX?
Per IMMX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001873835), Immix Biopharma Inc. generated $0 in revenue, -$29.4M in net income, and -$24.7M in free cash flow against $104.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IMMX trading relative to its 50-day, 200-day, and 52-week technical levels?
IMMX last traded at $7.68 (-3.76% on volume of 1,382,240 shares), positioning the stock -29.61% below its 50-day simple moving average ($10.91) and -19.16% below its 200-day simple moving average ($9.50). Across its 52-week range of $2.85 to $15.10, IMMX sits at the 39.4% percentile with a 14-day RSI of 35.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.72 to $8.64).
IMMX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IMMX stock moving today?
Why IMMX Stock dropped -3.76% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 29/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
IMMX — Immix Biopharma Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:34:03Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, IMMX scores 29 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The score is built from five pillars, each out of 20. The Fundamental Cash Engine scores 6/20, reflecting ROIC of -35% and an FCF yield of -3.73%. Whale 13F Flow scores 4/20 for institutional accumulation and options positioning. Insider Conviction scores 3/20 based on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 6/20, reflecting Beta of 1.0 and sector sensitivity. Forensic Balance Sheet scores 10/20, citing Altman Z 2.5, Piotroski F 2/9, and Debt/Equity 0.5. For a prospective investor, the pillar profile indicates that the company is consuming cash rather than generating it, that institutional and insider signals in the rating are weak, and that the balance sheet is the strongest of the five pillars yet still only moderate. Upside drivers would need to come from outside the reported cash engine, and the rating offers no quantified valuation support for that case.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-30.0M | $-29.4M | N/A | $-24.7M | $93.9M | N/A |
| FY 2024 | $0.0M | $-22.7M | $-21.6M | N/A | $-15.8M | $17.7M | N/A |
| FY 2023 | $0.0M | $-16.1M | $-15.4M | N/A | $-11.4M | N/A | N/A |
Per the SEC financials, operating losses widened from $-16.1M in FY 2023 to $-30.0M in FY 2025, with net losses following the same trajectory. Gross, operating, and net margins are each reported as 0% in the market data. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 2.5, and the Piotroski F-Score is 2/9. Reported cash rose from $17.7M in FY 2024 to $93.9M in FY 2025, while debt is not available in source data for any period; the Debt/Equity ratio is listed as 0.5 in the rating.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the headlines are: a Yahoo Finance report on a modest fair value lift after split analyst revisions; an Investing.com report on Morgan Stanley initiating coverage with an overweight rating; a TradingView estimates page; a Simply Wall Street stock price page; a GlobeNewswire release on participation in the 45th Annual J.P. Morgan Healthcare Conference; and a Stock Titan report on BlackRock reporting a passive stake above 5%. All items are tagged YELLOW with "MARKET WIRE" impact labels. The Butterfly Supply-Chain Graph reports no supply chain and no proprietary signals, so no proprietary catalyst signals are available. Risk watch items per the financials include continued operating losses and negative free cash flow in each reported period.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The only sector context provided is Health Care / Biotechnology: Pharmaceutical Preparations.
Open Questions
- What is the company's product pipeline and revenue model, given zero reported revenue across three fiscal years?
- What is the total debt position, since the debt field is N/A for every period while the rating cites Debt/Equity of 0.5?
- How much of the $93.9M FY 2025 cash balance is available after operating cash burn of $24.7M in free cash flow?
- What are the P/E, EV/EBITDA, and EPS figures, given that all are unavailable while net losses are reported?
- What do the split analyst revisions referenced in the news feed actually change in valuation terms?
IMMX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Immix Biopharma Inc. (IMMX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 9h ago
Immix Biopharma (IMMX) Stock Sees Modest Fair Value Lift After Split Analyst Revisions Yahoo Finance report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 12h ago
Morgan Stanley initiates Immix Biopharma stock with overweight rating Investing.com report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 15h ago
Immix Biopharma, Inc. Estimates – NASDAQ:IMMX TradingView report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall Street • 18h ago
Immix Biopharma (NasdaqCM:IMMX) Stock Price Simply Wall Street report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 21h ago
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference GlobeNewswire report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
BlackRock reports a passive stake above 5% in Immix Biopharma (IMMX). Stock Titan report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingView • 1d ago
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength? TradingView report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
IMMX Bull vs. Bear Conversation Board — What's Your Call at $7.68?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IMMX 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $7.02 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is IMMX (E • RQD 29/100) a Buy at $7.98?
Welcome to the IMMX (Immix Biopharma Inc.) Roar Pit. Current RQD Composite is 29/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $6.46 (-19.0%)
Spot @ $7.98 Pump the brakes on IMMX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on IMMX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Immix Biopharma Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $9.34 (+17.0%)
Spot @ $7.98 IMMX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on IMMX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $7.98 (52-wk range $2.85 - $15.10), any beat on forward guidance forces shorts and underweight funds to chase.